Exploration of the BaSeL stellar library for 9 F-type stars COROT potential targets

The Basel Stellar Library (BaSeL models) is constituted of the merging of various synthetic stellar spectra libraries, with the purpose of giving the most comprehensive coverage of stellar parameters. It has been corrected for systematic deviations detected in respect to UBVRIJHKLM photometry at solar metallicity, and can then be considered as the state-of-the-art knowledge of the broad band content of stellar spectra. In this paper, we consider a sample of 9 F-type stars with detailed spectroscopic analysis to investigate the Basel Stellar Library in two photometric systems simultaneously, Johnson (B-V, U-B) and Stromgren (b-y, m_1, and c_1). The sample corresponds to potential targets of the central seismology programme of the COROT space experiment, which have been recently observed at OHP. The atmospheric parameters T_eff, [Fe/H], and log g obtained from the BaSeL models are compared with spectroscopic determinations as well as with results of other photometric calibrations. For a careful interpretation of the BaSeL solutions, we computed confidence regions around the best $\chi$^2-estimates and projected them on T_eff-[Fe/H], T_eff-log g, and log g-[Fe/H] diagrams. (Abridged)Comment: 16 pages, LaTeX2e; version accepted for publication in the new A&A Journal: minor changes + figures in black and white for better readabilit

Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major

Significant advances in supportive care for patients with transfusion-dependent thalassemia major (TDT) have improved patients' life expectancy. However, transfusion-associated iron overload remains a significant barrier to long-term survival with good quality of life. Today, allogeneic hematopoietic stem cell transplantation (HSCT) is the current curative standard of care. Alongside selection of the best available donor, an optimized conditioning regimen is crucial to maximize outcomes for patients with TDT undergoing HSCT. The aim of this retrospective analysis was to investigate the role of busulfan-fludarabine-based and treosulfan-fludarabine-based conditioning in TDT patients undergoing HSCT. We included 772 patients registered in the European Society for Blood and Marrow Transplantation (EBMT) database who underwent first HSCT between 2010 and 2018. Four hundred ten patients received busulfan-fludarabine-based conditioning (median age 8.6 years) and 362 patients received treosulfan-fludarabine-based conditioning (median age 5.7 years). Patient outcomes were retrospectively compared by conditioning regimen. Two-year overall survival was 92.7% (95% confidence interval: 89.3-95.1%) after busulfan-fludarabine-based conditioning and 94.7% (95% confidence interval: 91.7-96.6%) after treosulfan-fludarabine-based conditioning. There was a very low incidence of second HSCT overall. The main causes of death were infections, graft-versus-host disease, and rejection. In conclusion, use of busulfan or treosulfan as the backbone of myeloablative conditioning for patients with TDT undergoing HSCT resulted in comparably high cure rates. Long-term follow-up studies are warranted to address the important issues of organ toxicities and gonadal function.Transplantation and immunomodulatio

Pulsational content and abundance analysis of some delta Scuti stars observed by CoRoT

International audienceSeveral delta Sct stars were photometrically monitored with the satellite CoRoT and observed in high-resolution spectroscopy from ground. We present here the preliminary results of the abundance analysis of several potential CoRoT targets. Moreover, new insights are given about the problem of the huge number of detected frequencies by comparing delta Sct stars with normal A-type stars

Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major

Significant advances in supportive care for patients with transfusion-dependent thalassemia major (TDT) have improved patients’ life expectancy. However, transfusion-associated iron overload remains a significant barrier to long-term survival with good quality of life. Today, allogeneic hematopoietic stem cell transplantation (HSCT) is the current curative standard of care. Alongside selection of the best available donor, an optimized conditioning regimen is crucial to maximize outcomes for patients with TDT undergoing HSCT. The aim of this retrospective analysis was to investigate the role of busulfan–fludarabine-based and treosulfan–fludarabine-based conditioning in TDT patients undergoing HSCT. We included 772 patients registered in the European Society for Blood and Marrow Transplantation (EBMT) database who underwent first HSCT between 2010 and 2018. Four hundred ten patients received busulfan–fludarabine-based conditioning (median age 8.6 years) and 362 patients received treosulfan–fludarabine-based conditioning (median age 5.7 years). Patient outcomes were retrospectively compared by conditioning regimen. Two-year overall survival was 92.7% (95% confidence interval: 89.3–95.1%) after busulfan–fludarabine-based conditioning and 94.7% (95% confidence interval: 91.7–96.6%) after treosulfan–fludarabine-based conditioning. There was a very low incidence of second HSCT overall. The main causes of death were infections, graft-versus-host disease, and rejection. In conclusion, use of busulfan or treosulfan as the backbone of myeloablative conditioning for patients with TDT undergoing HSCT resulted in comparably high cure rates. Long-term follow-up studies are warranted to address the important issues of organ toxicities and gonadal function